Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Exercise may help people with Parkinson's disease improve their balance, ability to move around and quality of life, according to a new study. In the study, 231 people with Parkinson's disease either received their usual care or took part in an exercise programme of 40 to 60 minutes of balance and leg strengthening exercises three times a week for six months.

  • Glycotherapy is useful for those with drug resistant tumour. Less toxification is the beauty of this therapy. Tunicamycin is an antibiotic being used in the therapy. It blocks cell cycle progression and targets only proliferating cells," Professor Dipak K Banerjee at the Department of Biochemistry, School of Medicine, University of Puerto Rico in USA said.

  • 16 January 2015
    USFDA approves first-of-kind device to treat obesity - VBLOC

    The U.S. Food and Drug Administration today approved the Maestro Rechargeable System for certain obese adults, the first weight loss treatment device that targets the nerve pathway between the brain and the stomach that controls feelings of hunger and fullness.
    The Maestro Rechargeable System, the first FDA-approved obesity device since 2007, is approved to treat patients aged 18 and older who have not been able to lose weight with a weight loss program, and who have a body mass index of 35 to 45 with at least one other obesity-related condition, such as type 2 diabetes.

    [adsense:336x280:8701650588]

  • Focused academic research can go a long way in strengthening the health sector, and provide solutions to many challenges facing the country in providing accessible and affordable health care to all, particularly the needy and vulnerable. Similarly, IT can play a crucial role as an enabler to address several critical issues in the country’s health sector.

  • Bristol-Myers Squibb (BMS) Company and the California Institute for Biomedical Research (Calibr) entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows BMS to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration.

  • Quintiles today announced that the company was awarded “Best Contract Research Organization” at the annual SCRIP Awards for the third year in-a-row. This is the company’s fourth award received in this category in the last five years. The SCRIP Awards acknowledge excellence in the biopharmaceutical industry, based on judging by an independent panel of 12 life sciences experts.

  • Three-year outcomes from an ongoing clinical trial suggest that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells may induce sustained remission in some people with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most common form of MS, a progressive autoimmune disease in which the immune system attacks the brain and spinal cord. The trial is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN).

Subscribe to Pharma News